SRSC 355

Drug Profile

SRSC 355

Alternative Names: SGX 355

Latest Information Update: 15 Apr 2004

Price : $50

At a glance

  • Originator Sirus
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 11 Mar 2004 Discontinued - Preclinical for Neuropathic pain in United Kingdom (unspecified route)
  • 08 Apr 2003 SynGenix is now called Sirus
  • 11 Dec 2002 Preclinical trials in Neuropathic pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top